September JAAD: Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)
AAD's Dialogues in Dermatology · AAD
September 20, 2023
Audio is streamed directly from the publisher (resources.aad.org) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Andrew Blauvelt, MD, FAAD interviewed by Jackie Dosal, MD, FAAD